IOFLUPANE I-123

Post-LOE

ioflupane i-123

Curium Pharma
ANDAINTRAVENOUSSOLUTION
Approved
Mar 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100

Mechanism of Action

Radiopharmaceutical Activity

Pharmacologic Class:

Radioactive Diagnostic Agent

Company
Curium Pharma
Curium Pharma
France - Paris
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers